Autoimmune blistering diseases (AIBD) encompass several autoimmune diseases which manifest with blisters and/or erosions on the skin and/or mucous membranes. Patogenetically, autoantibodies attach to the structural proteins of the skin, which are responsible for the intercellular contact between keratinocytes and the adhesion of basal keratinocytes to the dermis. Autoantibodies mechanically separate the cells subsequently leading to separation, blisters, and erosions formation. In pemphigus diseases, blisters form within the epidermis, while in pemphigoid diseases they form under the epidermis. Early and accurate diagnosis of autoimmune bullous dermatoses is crucial for therapy and prognosis. The diagnosis is based on anamnesis, clinical picture, histopathology, direct immunofluorescence (DIF), and determination of circulating autoantibodies. The gold standard for diagnosis is direct immunofluorescence microscopy. Circulating autoantibodies can be detected via indirect immunofluorescence (IIF) of tissue substrates including human skin, monkey esophagus, or recombinant forms of the different target antigens. ELISA systems use various recombinant antigens, and apart from disease detection, they are used for monitoring the disease activity which can be helpful for treatment adjustment. Immunoblotting is an additional diagnostic method that is used in specialized laboratories when the final diagnosis has not been established by previous methods. The new method – BIOCHIP based on indirect immunofluorescence allows the analysis of several recombinant antigens at once. In addition, BIOCHIP mosaic consists of the standard tissue sections for indirect immunofluorescence and the recombinant monospecific IIF substrates. This approach allows autoantibody screening and confirmatory discrimination in a single incubation, and by that enables a time-effective approach, particularly in diagnostically difficult cases.